A number of clinical trial data provided a peek into the stiff competition developing in the obesity treatment space as three drug giants battle for a piece of what is estimated to be a $100 billion market by the end of the decade.
Novo Nordisk's greatest competition remains Eli Lilly . The two are already fierce competitors in the diabetes care and insulin space, and Eli Lilly has a number of competing products on the market and in the pipeline.for its oral candidate, orforglipron, showing up to 14.7% weight loss. On Monday, it revealed Phase 2 data for its experimental weight loss injection, retatrutide, showing up to 24% weight loss.
Pfizer , meanwhile, is finding its footing in the oral treatment race. Pfizer said it would pursue its twice-daily pill, danuglipron, over its once-daily candidate, lotiglipron, due to concerns of elevated liver damage risk in early-stage trials. The company is moving the drug into Phase 2 to figure out the most effective dosing but said it will also work on trying to make it a once-daily pill in order to compete with Rybelsus and orforglipron.
half of US adults would be willing to pay $100 per month for a weight loss drug, the cost of Wegovy and Ozempic ranges from more than $800 to more than $1,300 out of pocket.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Litecoin (LTC) Soars to 14-Month High Above $100, Bitcoin (BTC) Reclaims $30K (Weekend Watch)BitcoinSV is today's best performer from the top 50 with a 18% surge.
Read more »
These Luxury Silk PJs Are On Sale For Under $100Sound the alarm (clock): Luxury silk pajama brand SilkSilky has slashed its summer 2023 collection prices by up to 42%
Read more »
What is Shein? The $100 billion fast-fashion company explained.Shein's rise: How the wildly popular but controversial Chinese brand became the most feared fast-fashion retailer in the world
Read more »
Simone Biles returning to competition in August for first meet since 2020 OlympicsDon't call it a comeback. Simone Biles has been here for years.
Read more »
Tesla Deliveries to Show Whether Price Cuts Are Paying OffElectric-car maker Tesla is expected to release second-quarter global deliveries amid stiffening EV competition
Read more »